Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
BRVE · Why this verdict
Why Braveheart Bio (BRVE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Braveheart Bio is a pre-revenue biotech where insiders bought $159M (8.823% of market cap), but the shares are in a downtrend, quality is below the engine's floor and the latest quarter missed badly.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Biotechnology is a binary industry and quality of 2.5 reflects zero revenue and margins, so value depends on clinical outcomes. Suitability rationale | Clinical milestones are reached within 12 months. | →Stable |
| CounterA $1.8B market cap is below institutional reach, so a positive readout could attract new holders quickly. | ||
Thirteen insider purchases totalling $159,034,950 (8.823% of market cap) with no sales show strong internal conviction. Insider breakdown | Net insider buying remains positive over the next 12 months. | ↓Deteriorating |
| CounterLarge purchases may relate to a financing round and do not reduce clinical risk. | ||
The latest quarter reported a loss of 2.51 per share against an estimated profit of 2.69, a miss of about 193%. Earnings | Results move back in line with estimates. | →Stable |
| CounterA one-quarter sample in a pre-revenue company can be dominated by non-recurring items. | ||
Momentum at 1.6 is far below the 4.5 threshold, with falling on-balance volume and the price below its trend. Momentum breakdown | Momentum recovers above 4.5. | ↑Improving |
| CounterThe shares may already reflect the bad news after a 15% downside to the stop level. | ||
Biotechnology is a binary industry and quality of 2.5 reflects zero revenue and margins, so value depends on clinical outcomes.
→StableSuitability rationale
- Expectation
- Clinical milestones are reached within 12 months.
CounterA $1.8B market cap is below institutional reach, so a positive readout could attract new holders quickly.
Thirteen insider purchases totalling $159,034,950 (8.823% of market cap) with no sales show strong internal conviction.
↓DeterioratingInsider breakdown
- Expectation
- Net insider buying remains positive over the next 12 months.
CounterLarge purchases may relate to a financing round and do not reduce clinical risk.
The latest quarter reported a loss of 2.51 per share against an estimated profit of 2.69, a miss of about 193%.
→StableEarnings
- Expectation
- Results move back in line with estimates.
CounterA one-quarter sample in a pre-revenue company can be dominated by non-recurring items.
Momentum at 1.6 is far below the 4.5 threshold, with falling on-balance volume and the price below its trend.
↑ImprovingMomentum breakdown
- Expectation
- Momentum recovers above 4.5.
CounterThe shares may already reflect the bad news after a 15% downside to the stop level.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 4.0 |
| OBV | 6.6 |
| MA position | 2.5 |
| Volume | 1.7 |
Sentiment
7.2/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸Analyst upside: 142%
Insider
5.0/10data confidence 50%- ▸Insider dollar basis unavailable — not scored
Peer rank
5.9/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.1 |
| support resistance | 9.2 |
| 52w position | 1.7 |
Risk (lower is worse)
4.5/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 3.4 |
| volatility | 0.0 |
| debt equity | 10.0 |
Catalyst
1.7/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- ASYMMETRY:7.0>=1.5
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:26d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.7<4.5
Warning (1)
- INSIDER:UNAVAILABLE
Reward-to-Risk
7.04
Upside
+105.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.7B) below institutional reach
SuitabilitySpeculative — Drawdown -42% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 3.7<4.5 outcome against Value at 9.0 and asymmetric R:R of 7.04.
The strongest dimensions are Value at 9.0, Sentiment at 7.2, and Technical at 6.3; the weakest are Catalyst at 1.7, Quality at 2.5, and Momentum at 3.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 7.04 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying
Trip ifNet insider buying over a trailing 90 days falls below $20M from the current $159M.
- P2Latest Quarter Miss
Trip ifEPS beats estimates in at least 2 consecutive quarters.
- P3Weak Price Momentum
Trip ifMomentum score rises above 4.5 from the current 1.6.
- P4Binary Biotech Risk
Trip ifQuality score rises above 4.0 from the current 2.5.